The primary objectives of this core, the Anatomic and Functional Imaging Core, are to provide P01 projects with an extensive array of research-based imaging technologies; the support of a sophisticated core of highly trained professional imaging physicians, scientists, and technologists; and the database maintenance and data correlation support required to pursue research aimed at improving multiple myelosis (MM) diagnosis, prognosis, and treatment through clinical and preclinical research. These objectives will be met through the accomplishment of the following specific aims:
Specific Aim 1. Offer anatomic and functional imaging for myeloma patients and animal models. The core will bring together state-of-the-art anatomic and functional imaging resources to provide the specific imaging capabilities necessary to enable each P01 project to accomplish its individual aims. This impressive technological support will be delivered by a dedicated team of 2 radiologists with extensive institutional support and the assistance of consultants and collaborators who are world-renown in the modalities used.
Specific Aim 2. Perform guided biopsies providing rapid and accurate visual assessment of disease distribution in patients and animal models, in the skeletal system, and in soft tissues. This service will allow investigators to identify the most metabolically active regions (sentinel lesions).
Specific Aim 3. Maintain and correlate databases from anatomic and functional imaging studies. Core B will continue to maintain databases (i.e., MRI scans, skeletal surveys, fluorodeoxyglucose (FDG) PET scans, CT findings, etc.) already in use during the current funding cycle, and establish new databases as needed. Databases contain quantitative results of each finding that the professional imaging specialists feel is relevant for the modality involved. These databases are periodically converted to an Excel spreadsheet format and e-mailed to Cancer Research and Biostatistics providers for data analysis and correlation, a process that has already resulted in many new insights into the biological behavior of multiple myeloma. Thus, by providing anatomic and functional imaging, as well as database management and correlation with clinical data, Core B will enable P01 projects to pursue research aimed at improving MM diagnosis, prognosis, and treatment through clinical and preclinical research.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Arkansas for Medical Sciences
Little Rock
United States
Zip Code
Rasche, L; Alapat, D; Kumar, M et al. (2018) Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia :
Went, Molly; Sud, Amit; Försti, Asta et al. (2018) Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Nat Commun 9:3707
Mehdi, Syed J; Johnson, Sarah K; Epstein, Joshua et al. (2018) Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes. Br J Haematol :
Rasche, Leo; Angtuaco, Edgardo J; Alpe, Terri L et al. (2018) The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood 132:59-66
Went, M; Sud, A; Law, P J et al. (2017) Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach. Blood Cancer J 7:e573
McDonald, James E; Kessler, Marcus M; Gardner, Michael W et al. (2017) Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. Clin Cancer Res 23:1981-1987
Rasche, Leo; Weinhold, Niels; Morgan, Gareth J et al. (2017) Immunologic approaches for the treatment of multiple myeloma. Cancer Treat Rev 55:190-199
Rasche, L; Chavan, S S; Stephens, O W et al. (2017) Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun 8:268
Jethava, Yogesh S; Mitchell, Alan; Epstein, Joshua et al. (2017) Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants. Clin Cancer Res 23:2665-2672
Schinke, Carolina; Hoering, Antje; Wang, Hongwei et al. (2017) The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica 102:e313-e316

Showing the most recent 10 out of 290 publications